|In vitro (25°C)||DMSO||113 mg/mL (199.29 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||20 mg/mL (35.27 mM)|
|In vivo||30% PEG400/0.5% Tween80/5% propylene glycol||30 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||17.63 mL||88.17 mL||176.34 mL|
|0.5 mM||3.53 mL||17.63 mL||35.27 mL|
|1 mM||1.76 mL||8.82 mL||17.63 mL|
|5 mM||0.35 mL||1.76 mL||3.53 mL|
*The above data is based on the productmolecular weight 567.1. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
|Synonyms||BMS-599626, BMS599626, AC-480|
Erlotinib hydrochloride is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
AG-17 is an inhibitor of EGF receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.
AV-412 is an EGFR/HER2 inhibitor that binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth facto…
CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as i…
WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant pati…
Lapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.
PD153035 is an extremely potent and specific inhibitor of the tyrosine kinase activity of EGFR.